SCHEMBL607402

SCHEMBL607402

OC(CN1CCN(Cc2cc(Cl)cc(Cl)c2)CC1)Cn1c2ccccc2c2cc(Br)ccc21

nearest known ligand 0.69

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAD52 P43351 2/20 0.69
MEN1 O00255 1/20 0.69
KMT2A Q03164 1/20 0.69
LMNA P02545 4/20 0.66
GAA P10253 1/20 0.66
MAPK1 P28482 3/20 0.58
HTT P42858 3/20 0.58
BAX Q07812 1/20 0.57
DNM1 Q05193 2/20 0.57
MAPT P10636 5/20 0.56
TP53 P04637 2/20 0.56
CYP3A4 P08684 1/20 0.56
ALOX15 P16050 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
POLB P06746 1/20 0.52
NLRP1 Q9C000 1/20 0.51
ATM Q13315 1/20 0.50
KDM4E B2RXH2 1/20 0.49
ALDH1A1 P00352 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL607023 0.88 LMNA (0.73) RAD52MEN1KMT2ALMNAGAA
SCHEMBL6815606 0.88 MEN1 (0.88) RAD52MEN1KMT2ALMNAGAA
SCHEMBL609372 0.88 MEN1 (0.67) RAD52MEN1KMT2ALMNAGAA
SCHEMBL607057 0.88 MEN1 (0.69) RAD52MEN1KMT2ALMNAGAA
SCHEMBL607210 0.88 MEN1 (0.69) RAD52MEN1KMT2ALMNAGAA
SCHEMBL607481 0.86 MEN1 (0.67) RAD52MEN1KMT2ALMNAGAA
SCHEMBL607410 0.85 MEN1 (0.66) RAD52MEN1KMT2ALMNAGAA
SCHEMBL607384 0.85 LMNA (0.82) RAD52MEN1KMT2ALMNAGAA
SCHEMBL607619 0.84 LMNA (0.81) RAD52MEN1KMT2ALMNAGAA
SCHEMBL606781 0.83 LMNA (0.64) RAD52MEN1KMT2ALMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1237887-B1 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS SERONO LAB (CH) 2008-06-04 EP claimed
EP-1237887-A1 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS Applied Research Systems ARS Holding N.V. (AN) 2002-09-11 EP claimed
WO-2001029028-A1 9- (PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2001-04-26 WO claimed
US-8410110-B2 9-(piperazinylalkyl) carbazoles as Bax-modulators MERCK SERONO SA (CH) 2013-04-02 US disclosed
US-20120040933-A1 9-(PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2012-02-16 US disclosed
US-8053436-B1 9-(piperazinylalkyl) carbazoles as bax-modulators MERCK SERONO SA (CH) 2011-11-08 US disclosed
EP-1237887-B1 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS SERONO LAB (CH) 2008-06-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040933-A1 9-(PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS BCL2, BAX, BAD RAD52 3656/4885MEN1 3810/4885KMT2A 732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.